PBS reviews red tape for oncology drugs
Cancer drugs will be the first to benefit from a review of PBS prescribing restrictions and red tape.
In its newly-launched Post-market Review of Authority Required PBS Listings, the PBS said drugs for cancer had been identified as being among those with the highest regulatory burden. Therefore, these drugs will be included in the first tranche of medicines to be reviewed for consideration by the PBAC at its November 2014 meeting.
Easing of restrictions could mean movement of medicines from Authority Required to Authority Required